📊 BTCY Key Takeaways
Is Biotricity Inc.. (BTCY) a Good Investment?
Biotricity exhibits severe financial distress with negative stockholders' equity of -$34.2M, indicating the company is technically insolvent. Despite strong gross margins of 81.3%, the company burns cash operationally (-$698K in FCF) and cannot cover basic operating expenses, with a critical liquidity crisis evidenced by a current ratio of 0.21x and only $256.4K in cash.
Biotricity shows a potentially viable product model with strong gross margins and positive operating income, but the balance sheet and liquidity profile are severely distressed. Negative equity, very low cash, weak interest coverage, and negative operating/free cash flow materially outweigh the improvement in operating profitability, making the fundamentals highly fragile.
Why Buy Biotricity Inc.. Stock? BTCY Key Strengths
- Exceptional gross margin of 81.3% indicates strong pricing power and product unit economics
- Positive operating income of $996.7K demonstrates some operational profitability at the EBIT level
- Medical device sector with potential for recurring revenue if commercial traction improves
- High gross margin of 81.3% indicates strong unit economics and pricing power
- Positive operating income and 8.5% operating margin suggest progress toward operating scalability
- Capital expenditure is low, which limits cash demands from fixed-asset intensity
BTCY Stock Risks: Biotricity Inc.. Investment Risks
- Negative stockholders' equity of -$34.2M represents technical insolvency and existential bankruptcy risk
- Severe liquidity crisis with current ratio of 0.21x and only $256.4K cash against $38.2M total liabilities
- Negative operating cash flow of -$698K and free cash flow of -$727.8K indicates unsustainable cash burn with no clear path to profitability
- Net loss of -$2.1M on $11.7M revenue demonstrates inability to convert gross profits into bottom-line profitability
- Interest coverage ratio of 0.4x indicates inability to service debt obligations from operating earnings
- Negative stockholders equity of $-34.24M signals deep balance-sheet impairment
- Current ratio of 0.21x and cash of only $256.36K indicate acute near-term liquidity risk
- Net loss, negative operating cash flow, and 0.4x interest coverage raise sustainability and financing concerns
Key Metrics to Watch
- Cash burn rate and cash runway until depletion
- Operating cash flow trajectory toward positive territory
- Revenue growth rate and path to achieving positive net income
- Stockholders' equity recovery through capital raises or debt restructuring
- Debt service obligations and refinancing risk
- Operating cash flow trend relative to revenue growth
- Current liabilities coverage, including cash balance and current ratio
Biotricity Inc.. (BTCY) Financial Metrics & Key Ratios
💡 AI Analyst Insight
The current ratio below 1.0x warrants monitoring of short-term liquidity.
BTCY Profit Margin, ROE & Profitability Analysis
BTCY vs Healthcare Sector: How Biotricity Inc.. Compares
How Biotricity Inc.. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Biotricity Inc.. Stock Overvalued? BTCY Valuation Analysis 2026
Based on fundamental analysis, Biotricity Inc.. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Biotricity Inc.. Balance Sheet: BTCY Debt, Cash & Liquidity
BTCY Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Biotricity Inc..'s revenue has grown significantly by 307% over the 5-year period, indicating strong business expansion. The most recent EPS of $-1.66 indicates the company is currently unprofitable.
BTCY Revenue Growth, EPS Growth & YoY Performance
BTCY Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2026 | $3.6M | -$717.1K | $-0.04 |
| Q2 2026 | $3.3M | -$690.9K | $-0.03 |
| Q1 2026 | $3.2M | -$672.0K | $-0.03 |
| Q3 2025 | $3.0M | -$1.2M | $-0.05 |
| Q2 2025 | $2.9M | -$1.6M | $-0.07 |
| Q1 2025 | $3.0M | -$3.4M | $-0.41 |
| Q3 2024 | $2.5M | -$2.8M | $-0.34 |
| Q2 2024 | $2.4M | -$3.7M | $-0.44 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Biotricity Inc.. Dividends, Buybacks & Capital Allocation
BTCY SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Biotricity Inc.. (CIK: 0001630113)
📋 Recent SEC Filings
❓ Frequently Asked Questions about BTCY
What is the AI rating for BTCY?
Biotricity Inc.. (BTCY) has a Combined AI Rating of STRONG SELL from Claude (STRONG SELL) and ChatGPT (STRONG SELL) with 92% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are BTCY's key strengths?
Claude: Exceptional gross margin of 81.3% indicates strong pricing power and product unit economics. Positive operating income of $996.7K demonstrates some operational profitability at the EBIT level. ChatGPT: High gross margin of 81.3% indicates strong unit economics and pricing power. Positive operating income and 8.5% operating margin suggest progress toward operating scalability.
What are the risks of investing in BTCY?
Claude: Negative stockholders' equity of -$34.2M represents technical insolvency and existential bankruptcy risk. Severe liquidity crisis with current ratio of 0.21x and only $256.4K cash against $38.2M total liabilities. ChatGPT: Negative stockholders equity of $-34.24M signals deep balance-sheet impairment. Current ratio of 0.21x and cash of only $256.36K indicate acute near-term liquidity risk.
What is BTCY's revenue and growth?
Biotricity Inc.. reported revenue of $11.7M.
Does BTCY pay dividends?
Biotricity Inc.. pays dividends, with $0.1M distributed to shareholders in the trailing twelve months.
Where can I find BTCY SEC filings?
Official SEC filings for Biotricity Inc.. (CIK: 0001630113) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is BTCY's EPS?
Biotricity Inc.. has a diluted EPS of $-0.10.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is BTCY a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Biotricity Inc.. has a STRONG SELL rating with 92% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is BTCY stock overvalued or undervalued?
Valuation metrics for BTCY: ROE of N/A (sector avg: 15%), net margin of -17.7% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy BTCY stock in 2026?
Our dual AI analysis gives Biotricity Inc.. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is BTCY's free cash flow?
Biotricity Inc..'s operating cash flow is $-698.1K, with capital expenditures of $29.8K. FCF margin is -6.2%.
How does BTCY compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -17.7% (avg: 12%), ROE N/A (avg: 15%), current ratio 0.21 (avg: 2).